Questions about mesothelioma? Call 1-800-726-1860

hedy kindler mesothelioma

  • This field is for validation purposes and should be left unchanged.

Your message to us will be held in strict confidence. All requests for information by mesothelioma patients and their family members will be answered within 24 hours. Mesothelioma Treatment and Care Guides are sent to mesothelioma patients and families by overnight delivery.

Mesothelioma Specialist Spotlight – Dr. Hedy Kindler

Mesothelioma Specialist Spotlight – Dr. Hedy Kindler, University of Chicago

uch_005457-1Dr. Hedy Kindler is a Professor of Medicine at the University of Chicago. She is also the Medical Director, Gastrointestinal Oncology, Mesothelioma Program. Dr. Kindler is an internationally known and respected expert in the care of mesothelioma patients. She is active in the mesothelioma community having served as immediate past president of the International Mesothelioma Interest Group (IMIG).

Dr. Kindler is a graduate of the State University of New York in Buffalo Medical School. Her intern and residency years were at The University of California at Los Angeles Medical Center. Her Fellowship was done at Memorial Sloan Kettering Cancer Center in New York.

Since being in practice since 1995, she has been recognized by her peers and patients alike. She is an associate editor of Lung Cancer.   Her many accomplishments include articles, research, awards and speaking engagements, are her very devoted and grateful patients. Dr. Kindler serves on the Science Advisory Board of the Mesothelioma Foundation, a non-profit for mesothelioma, dedicated to supporting patients and scientists through research for a cure for mesothelioma. She has also been awarded the Selikoff Lifetime Achievement Award by the Asbestos Disease Awareness Organization for her work on behalf of mesothelioma victims.

Dr. Kindler is passionate about improving the quality of life for mesothelioma patients. She is leading clinical trials that are showing promising results.

We recently reviewed in detail one of Dr. Kindler’s current mesothelioma clinical trials using the drug Pembrolizumab. For information about that clinical trial and to read our review click here.

On a personal note, Dr. Kindler is easily accessible via email and devoted to improving patient outcomes.

  • This field is for validation purposes and should be left unchanged.

Your message to us will be held in strict confidence. All requests for information by mesothelioma patients and their family members will be answered within 24 hours. Mesothelioma Treatment and Care Guides are sent to mesothelioma patients and families by overnight delivery.

Recent Articles

Have a question? We can answer it!

Mesothelioma Questions

1-800-726-1860